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ABSTRACT 
 
Increased incidence of neuronal nuclear indentations is a well-known feature of the striatum 
of Huntington’s disease (HD) brains and, in Alzheimer’s disease (AD), neuronal nuclear 
indentations have recently been reported to correlate with neurotoxicity due to improper 
cytoskeletal/nucleoskeletal coupling. Initial detection of rod-shaped tau immunostaining in 
nuclei of cortical and striatal neurons of HD brains and in hippocampal neurons of early Braak 
stage AD led us to coin the term “tau nuclear rods (TNRs)”. Although TNRs traverse nuclear 
space, they in fact occupy narrow cytoplasmic extensions that fill indentations of the nuclear 
envelope and we will here refer to this histological hallmark as Tau-immunopositve nuclear 
indentations (TNIs). We reasoned that TNI formation is likely secondary to tau alterations as 
TNI detection in HD correlates with an increase in total tau, particularly of the isoforms with 
four tubulin binding repeats (4R-tau). Here we analyze transgenic mice that overexpress 
human 4R-tau with a frontotemporal lobar degeneration-tau point mutation (P301S mice) to 
explore whether tau alteration is sufficient for TNI formation. Immunohistochemistry with 
various tau antibodies, immunoelectron microscopy and double tau-
immunofluorescence/DAPI-nuclear counterstaining confirmed that excess 4R-tau in P301S 
mice is sufficient for the detection of abundant TNIs that fill nuclear indentations. Interestingly, 
this does not correlate with an increase in the number of nuclear indentations, thus suggesting 
that excess total tau or an isoform imbalance in favor of 4R-tau facilitates tau detection inside 
preexisting nuclear indentations but does not induce formation of the latter. In summary, here 
we demonstrate that tau alteration is sufficient for TNI detection and our results suggest that 
the neuropathological finding of TNIs becomes a possible indicator of increased total tau 
and/or increased 4R/3R-tau ratio in the affected neurons apart from being an efficient way to 
monitor pathology-associated nuclear indentations. 
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INTRODUCTION  
 
The presence of rod shaped nuclear structures in neurons in normal and pathological states is 
known for more than a century (7, 8, 19, 22). These include the rodlets of Roncoroni or 
intranuclear rodlets among others and there have been many efforts to identify their 
constituent proteins (20, 30). Such rodlets have been associated with various 
neurodegenerative diseases like frontotemporal lobar degeneration (FTLD) (29), Alzheimer´s 
disease (AD) (32) or Parkinson’s Disease (17). 
 
On the other hand, rod shaped indentations of the nuclear envelope are also frequent in 
neurons (15, 24), their incidence has been reported to change as a consequence of the 
synaptic activity of the neurons (28) and increased incidence has been known for decades in 
striatum of Huntington’s disease (HD) brain and more recently also in related CAG triplet 
repeat disorders patients (4, 23, 25) and cell and mouse models (10, 11, 34). Interestingly, 
neuronal nuclear indentations have also recently been reported in AD and correlate with the 
improper cytoskeletal/nucleoskeletal coupling that has been suggested as a novel mediator of 
neurotoxicity in tauopathies (13). 
 
Tauopathies are a group of neurodegenerative diseases characterized by altered metabolism 
and deposition of the neuronal microtubule associated protein tau (MAPT) (2, 18). The 
discovery of mutations in the MAPT gene as causative of familial FTLD-tau evidenced that tau 
alteration is sufficient to cause neurodegenerative disease (16). Apart from point mutations, 
FTLD-tau can also be caused by silent and intronic mutations that affect the alternative splicing 
event that generates tau isoforms with either three or four tubulin binding repeats (3R- and 
4R-tau), thus demonstrating that an imbalance in the 3R/4R-tau ratio is pathological per se. 
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Neuronal tau nuclear rods (TNRs) were recently described as nuclear rodlet-shaped tau 
immunostainings in neurons of cortex and striatum of HD brains (12, 27 and reviewed in 14) 
and in hippocampus of early Braak stage AD brains (12). TNRs appear to traverse the nuclear 
space (12, 27). However, immunoelectron microscopy or confocal analysis of tau 
immunofluorescence with a fluorescent nuclear counterstaining revealed that TNRs in brains 
of HD patients in fact occupy narrow cytoplasmic extensions that fill infoldings of the nuclear 
envelope (12) and we will here refer to this histological hallmark as Tau-immunopositive 
nuclear indentations (TNIs). TNI formation is likely secondary to tau alterations as TNI 
detection in HD correlates with an increase in total tau, particularly of the isoforms with four 
tubulin binding repeats (4R-tau). However, it cannot be ascertained that the formation of the 
TNIs is a direct consequence of tau alteration.  
 
Here we analyze transgenic mice that overexpress human 4R-tau with a FTLD-tau point 
mutation (P301S mice) to explore whether tau alteration is sufficient for the detection of TNIs. 
Immunohistochemistry with various tau antibodies, immunoelectron microscopy and double 
tau-immunofluorescence/DAPI-nuclear counterstaining confirmed that P301S 4R-tau 
overexpression in tauopathy mice is sufficient for the detection of abundant TNIs.  
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MATERIALS AND METHODS 
 
Transgenic mice 
P301S mice transgenic for the human tau gene in B6C3F1 background (33) were used. This 
mouse model carries a mutant (P301S) human MAPT gene encoding T34-tau isoform (1N4R); it 
is driven by the mouse prion-protein promoter (Prnp) on a B6C3H/F1 genetic background. A 
group of mice was analysed at the age of 20 weeks at which P301S mice show only learning 
deficits and another at the age of 36 weeks at which they also show motor deficits (33). A total 
of 6 mice at the age of 20 weeks (n=3 for WT, n=3 for P301S) and a total of 15 mice at the age 
of 36 weeks (n=6 for WT, n=9 for P301S) were analyzed. Tau KO mice (9) were also used in this 
study to demonstrate specificity of immunostaining with different anti-tau antibodies. 
 
All mice were housed at the Centro de Biología Molecular “Severo Ochoa” animal facility. Mice 
were housed four per cage with food and water available ad libitum and maintained in a 
temperature-controlled environment on a 12/12 h light-dark cycle with light onset at 07:00 h. 
Animal housing and maintenance protocols followed the guidelines of Council of Europe 
Convention ETS123, recently revised as indicated in the Directive 86/609/EEC. Animal 
experiments were performed under protocols (P15/P16/P18/P22) approved by the Centro de 
Biología Molecular Severo Ochoa Institutional Animal Care and Utilization Committee (Comité 
de Ética de Experimentación Animal del CBM, CEEA-CBM, Madrid, Spain). 
 
Human brain samples from HD subjects 
Brain specimens used in this study from frontal cortex and striatum of two HD subjects, were 
provided by the Neurological Tissue Bank of the IDIBAPS Biobank (Barcelona, Spain). Written 
informed consent for brain removal after death for diagnostic and research purposes was 
obtained from brain donors and/or next of kin. Procedures, information and consent forms 
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have been approved by the Bioethics Subcommittee of Centro Superior de Investigaciones 
Científicas (Madrid, Spain). The postmortem delay in tissue processing (PMI) was 5:00 and 5:30 
h. The neuropathological examination of these HD cases revealed a diagnosis of HD grade 3 
following the criteria of Vonsattel (26). 
 
Western Blot 
Mouse brains were quickly dissected on an ice-cold plate. Extracts were prepared by 
homogenizing the brain areas in ice-cold extraction buffer, consisting of 20 mM HEPES pH 7.4, 
100 mM NaCl, 20 mM NaF, 1% Triton X-100, 1 mM sodium orthovanadate, 1μM okadaic acid, 5 
mM sodium pyrophosphate, 30 mM β-glycerophosphate, 5 mM EDTA, and protease inhibitors 
(2 mM PMSF, 10 µg/ml aprotinin, 10 µg/ml leupeptin and 10 µg/ml pepstatin), and 
centrifuging at 15000 g for 15 min at 4 °C. The resulting supernatant was collected, and protein 
content determined by Bradford assay. Fifteen micrograms of total protein were 
electrophoresed on 10% SDS-polyacrylamide gel, transferred to a nitrocellulose membrane 
and blocked in TBS-T (150 mM NaCl, 20 mM Tris–HCl, pH 7.5, 0.05% Tween 20) supplemented 
with 5% non-fat dry milk or 5% BSA depending on the antibody used. Employed antibodies 
were anti-tau Tau5 (577801 from Calbiochem) and anti-β-actin clone AC-74 (A5316 from 
Sigma-Aldrich). The membranes were incubated with the primary antibody overnight at 4°C in 
TBS-T supplemented with 5% non-fat dry milk, washed in TBS-T, incubated with secondary 
HRP-conjugated anti-mouse IgG (P0447 from DAKO Cytomation) and developed using the ECL 
detection kit (Perkin Elmer).  
 
Immunohistochemistry and immunofluorescence 
For human samples, formalin fixed (4%, at least 3 weeks) paraffin embedded tissue from 
cortex and striatum were used. Sections (5 μm thick) were mounted on superfrost-plus tissue 
slides (Menzel-Gläser) and deparaffinized.  
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All 20 week-old mice (n=3 for WT, n=3 for P301S) and 26 week-old mice Tau KO (n=2) were 
sacrificed using CO2. Brains were immediately removed and dissected on an ice-cold plate and 
left hemispheres, processed for histology, were placed in 4% paraformaldehyde in Sorensen’s 
phosphate buffer overnight and then immersed in 30% sucrose in PBS for 72 h. Once 
cryoprotected, the samples were included in OCT compound (Sakura Finetek Europe), frozen 
and stored at -80°C until use. 30 µm sagittal sections were cut on a cryostat (Thermo 
Scientific), collected and stored free floating in glycol containing buffer (30% glycerol, 30% 
ethylene glycol in 0,02M phosphate buffer) at -20°C.   
All 36 week-old mice (n=6 for WT, n=9 for P301S) were sacrificed by intracardial perfusion 
under deep pentobarbital anesthesia (intraperitoneal injection) with 50 ml of 0.9% saline, 
followed by 50 ml of 4% paraformaldehyde in phosphate buffer. Their brains were 
immediately extracted and fixed overnight in the same fixative. Sagittal 50-µm-thick sections 
were obtained on a Leica VT1000S vibratome. 
For immunohistochemistry, sections were immersed in 0.3% H2O2 in PBS for 30 min to quench 
endogenous peroxidase activity and in the case of human samples treated with 10 mM pH 6.0 
citrate buffer heated by microwave during 15 min for antigen retrieval. Subsequently, sections 
were blocked for 1 h in PBS containing 0.5% Fetal Bovine Serum, 0.3% Triton X-100 and 1% BSA 
(Sigma-Aldrich) and incubated overnight at 4°C in PBS containing 0.3% Triton X-100 and 1% 
BSA with the corresponding primary antibody: anti-tau HT-7 (MN1000 from Thermo Scientific), 
anti-tau Tau5 (577801 from Calbiochem), anti-tau Tau1 (MAB342 from Chemicon), or anti-
phosphorylated tau AT8 antibody (MN1020 from Thermo Scientific). Finally, brain sections 
were incubated with anti-mouse secondary antibody and avidin-biotin complex using the Elite 
Vectastain kit (Vector Laboratories). Chromogen reactions were performed with 
diaminobenzidine (SIGMAFASTTM DAB, Sigma) for 10 min. Mouse sections were mounted on 
glass slides and coverslipped with Mowiol (Calbiochem) while human sections where 
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dehydrated and mounted with DePeX (Serva). Images were captured using an Olympus BX41 
microscope with an Olympus camera DP-70 (Olympus Denmark A/S).  
 
For immunofluorescence, series of sections used for quantification were set by pooling 
together every 8th section (thus, each series comprises 8–10 sections with each section 400 
µm apart from the nearest ones). Sections were incubated overnight with primary antibody 
HT-7, followed by washes and overnight incubation with secondary antibody conjugated with 
Alexa-555 fluorophore (Invitrogen). Finally, they were counterstained for 10 minutes with DAPI 
(Calbiochem, Merck KGaA) and mounted using FluorSave (Calbiochem, Merck KGaA). Images 
were obtained under a Zeiss LSM710 confocal system coupled to the invert Axioobserver 
microscope with a 63x, 1.4 numerical aperture oil immersion objective using the Zen2010B sp1 
software (Carl Zeiss). Images were processed using ImageJ 1.45s.  
 
Quantification of nuclei with indentations and TNIs 
For quantification, researcher was blind to genotype. As HT-7 signal is only detectable in P301S 
mice, we first analyzed the incidence of nuclear indentations by imaging only the DAPI signal. 
Then, a second analysis was performed in which both HT-7 and DAPI images were taken in 
order to determine the overlap between nuclear indentation and HT-7 positive TNIs. 
For analysis of nuclear indentation incidence, 4 randomly selected sections of each series were 
analyzed per animal (n=5 for WT, n=7 for P301S). In each section, nuclear rod shaped 
indentations were counted in a 135 × 135 µm field of CA1 pyramidal neurons of the 
hippocampus. A Z-stacking of 60 planes 0.3 µm apart from each other was covered, comprising 
100–150 nuclei of pyramidal neurons. The percentage of nuclei presenting indentations was 
calculated. 
For TNIs detection, three P301S mice and three WT mice were analyzed (one section per 
brain). The number of nuclei with HT-7 positive TNIs was counted in a 135 × 135 µm field of 
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CA1 pyramidal neurons of the hippocampus. A Z-stacking of 18 planes 0.3 µm apart from each 
other was covered, comprising around 50 nuclei of pyramidal neurons per image. The 
percentage of nuclei presenting HT-7 positive TNIs was calculated. 
 
Electron Microscopy 
For electron microscopy, sections from P301S mice subjected to immunohistochemistry with 
anti-tau HT-7 antibody (MN1000 from Thermo Scientific) were processed. Briefly, sections 
were post-fixed in 2% OsO4 for 1 h, dehydrated, embedded in Araldite and flat-mounted in 
Formvar-coated slides, using plastic cover slips. After polymerization, selected areas were 
photographed, trimmed, re-embedded in Araldite and resectioned at 1 μm. These semi-thin 
sections were rephotographed and resectioned in ultrathin sections. The ultrathin sections 
were observed in a Jen 2010 Joel transmission electron microscope (Peabody), without heavy 
metal staining to avoid confounding precipitates. 
 
Data analysis 
Statistical analysis was performed with SPSS 21.0 (SPSS® Statistic IBM®). Data are represented 
as means ± SEM. The normality of the data was analyzed by Shapiro-Wilk test. For 2 group 
comparison, two tail t-Student’s test (data with normal distribution) or Mann-Whitney U-test 
(data with non-normal distribution) was performed. A critical value for significance of p<0.05 
was used throughout the study. 
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RESULTS 
 
Increased 4R-tau and detection of TNIs in cortex, striatum and hippocampus of P301S mice 
 To investigate if tau alteration is sufficient to induce the appearance of TNIs, we decided to 
analyze P301S mice. These mice express, under the control of the mouse prion promoter 
(MoPrP), a cDNA construct encoding the human tau (1N4R) isoform with one N-terminal insert 
and four tubulin binding repeats harboring the P301S FTLD-tau mutation (3) (Fig. 1A). We first 
confirmed by western blot the overexpression of 4R-tau in these mice, which resulted in 
dramatically increased total tau levels in the three analyzed areas: cortex, hippocampus and 
striatum of P301S mice with respect to wild type (WT) mice (Fig. 1B; n=3; t-Student, **p<0.01, 
***p<0.001). 
 
To explore whether TNIs can be detected in the brain of P301S mice, we performed 
immunohistochemistry on brain sections from WT and P301S mice at two different ages: 20 
weeks at which P301S mice show only learning deficits and 36 weeks at which they also show 
motor deficits (33) to study possible progression with age and disease phenotype. 
Immunostaining was performed with four different tau antibodies. On one hand, HT-7 and 
Tau5 antibodies that detect tau independently of its phosphorylation status and, on the other 
hand, Tau1 and AT8 antibodies that recognize a portion of the tau molecule only when it does 
not contain phosphorylated residues (Tau1) or only when phosphorylated at Ser202 and 
Thr205 (AT8). Out of these four antibodies, HT7 recognizes only transgenic tau as its epitope 
sequence (PPGQK) is not conserved in mouse (SPAQK) (21). On the contrary, the epitopes of 
Tau5, Tau1 and AT8 are conserved between mouse and human (21) and these antibodies 
detect both endogenous and transgenic tau protein. 
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With the three non phospho-tau antibodies, we were able to detect the presence of abundant 
TNIs in the three analyzed areas: cortex, hippocampus and striatum of P301S mice (Fig. 2A and 
C) whereas no TNIs were detected in WT mice and no tau signal was found in tau KO mice (Fig. 
2B). Interestingly, with the phospho-tau antibody (AT-8), TNIs were observed only in cortex of 
P301S mice and they were less abundant (Fig. 2C). Older mice showed slightly higher TNI 
incidence and, interestingly, wider and more complex TNIs were found in these older mice 
particularly with the Tau1 antibody that recognizes only unphosphorylated tau. With all 
antibodies and most remarkably with Tau1, the TNIs observed in P301S mice look very similar 
to those previously reported in cortex and striatum of HD patients (12), as evidenced by 
immunohistochemistry with the HT-7 antibody on HD samples (Fig. 2D).  
 
To verify that these so called TNIs in P301S mice really fill nuclear indentations as previously 
shown for the rod shaped immunostaining reported in HD brains, we performed 
immunoelectron microscopy. P301S brain sections were subjected to DAB-
immunohistochemistry with the HT-7 antibody. Examples of stained cortical neurons are 
shown in figure 3 depicting frequent indentations of the nuclear envelope with tau-
immunoreactivity evidenced by the presence of DAB precipitates inside the invagination. 
These are very similar to the neuronal nuclear indentations harboring tau immunoreactivity in 
the brain of HD patients (12). As also shown in Fig. 3, TNIs can adopt different shapes and sizes 
in neurons from P301S mice. 
 
No difference in the incidence of nuclear indentations between P301S and WT mice 
We then aimed to test whether appearance of TNIs in P301S mice was simply due to excess 
tau entering already formed nuclear indentations or whether the tau transgene also induced 
increased formation of nuclear indentations. To be able to simultaneously quantify TNIs and 
nuclear indentations we decided to optimize a method of HT-7-immunofluorescence with DAPI 
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nuclear counterstaining. Confocal analysis of brain tissue from P301S mice confirmed that we 
were able to efficiently screen each nucleus for the presence of HT-7 immunoreactive rods and 
for nuclear indentations independently by analyzing stacks of images encompassing the entire 
depth of the stained nuclei and then explore the degree of coincidence in the merged images. 
HT-7 immunoreactive nuclear grooves are efficiently observed by this technique in neurons 
from the three analyzed areas: cortex, hippocampus and striatum of P301S mice (Fig. 4). 
 
For quantification of the incidence of HT-7 immunoreactive rods and of nuclear indentations in 
both P301S and WT mice, we decided to focus on the CA1 region of the hippocampus as 
neuronal bodies are concentrated in a layer thus allowing quantification of a higher number of 
neurons per field. In good agreement with the immunohistochemistry data shown in Fig 2, 
immunufluorescence with HT-7 antibody did not detect TNIs in WT mice, despite the presence 
of nuclear indentations evidenced by DAPI nuclear counterstaining (Fig. 5A). In contrast, 
approximately 20% of neurons in CA1 region of the hippocampus of P301S mice show HT-7 
positive TNIs of different shapes that fill most of the nuclear invaginations detected by DAPI 
(Fig. 5A-B). Interestingly, there was not a significant difference between incidence of nuclear 
indentations in WT and P301S mice. More precisely, 23±1.7% of nuclei in CA1 region of WT 
mice presented indentations versus 21±4.4% of the nuclei in CA1 region of P301S mice, thus 
demonstrating that the increased incidence of TNIs in P301S mice is not due to increased 
incidence of nuclear indentations. 
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DISCUSSION 
 
The present study shows that overexpression of P301S 4R-tau in cortex, hippocampus and 
striatum of a tauopathy transgenic mouse model results in formation of TNIs that highly 
resemble the TNIs recently reported in cortical and striatal neurons of HD patients (12, 27). 
These TNIs consist on an invagination of the nuclear envelope filled with tau immunoreactive 
material. The detection of TNIs in P301S mice does not correlate with an increase in the 
incidence of nuclear indentations, as the percentage of nuclei with indentations was similar 
between P301S and WT mice.  
 
In AD, the most prevalent neurodegenerative disease with tau pathology, nuclear indentations 
have recently been reported and suggested to contribute to neurotoxicity as a consequence of 
improper cytoskeletal/nucleoskeletal coupling (13) and TNIs have also been observed by 
immunohistochemistry with tau antibodies in hippocampal neurons of patients at early Braak 
stage of AD (12). As mentioned, HD is also characterized by tau alterations, namely increased 
level of total tau and an imbalance of the 4R/3R-tau ratio in favor of the 4R- tau isoform (12, 
27; reviewed in 14). Interestingly, increased incidence of nuclear indentations in striatal 
neurons of HD patients has been known for decades based on ultrastructural analysis (4, 23). 
In view of this, we initially reasoned that TNI detection in HD and in P301S mice might likely 
arise from increased formation of nuclear indentations, maybe as a consequence of 
overstabilized microtubules due to excess 4R-tau, thus leading to microtubule bundling that in 
turn would push and deform the nuclear envelope. However, here we found that excess 4R-
tau in P301S mice does not result in increased incidence of nuclear indentations. This suggests 
that TNI detection in HD neurons might simply be due to the presence inside the nuclear 
indentations of tau molecules above threshold for immunohistochemical detection, as a result 
of excess tau and/or increased 4R/3R-tau as these features are what HD patient and P301S 
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mouse neurons have in common. Therefore, immunohistological detection of TNIs in 
histopathological analysis of human brain pathologies and mouse models might become an 
indicator of excess total tau content or a 4R/3R-tau imbalance in the affected neurons.  
 
In line with the latter, we do not believe that the P301S point mutation in transgenic tau 
molecules in P301S mice plays a significant role in the here reported detection of TNIs, as we 
suspect that similar incidence of TNIs would be present in the brains of transgenic mice with 
equivalent overexpression of 4R-wild type tau. Although the experiment to prove this has not 
been performed. 
 
Although the incidence of nuclear indentations is similar in P301S and WT mice, it is still 
possible that tau entering into the nuclear indentation is microtubule-driven with tau inside 
the invagination acting as a MAP. In fact, immunoelectron microscopy images often show that 
tau-immunoreactivity adopts an ordered parallel distribution inside the indentations both in 
HD human tissue (12) and P301S mice. Interestingly, we have also detected MAP2 positive 
nuclear rods in striatum of HD and control subjects (6). Furthermore, in case that some of the 
structures reported in the past as intranuclear rodlets coincide with TNIs, there are reports of 
intranuclear rodlets being positive for class III β-tubulin in multiple human neuronal types (30) 
and in mouse dopaminergic neurons (17, 31). 
 
Another mechanism for tau accumulation inside the nuclear indentation might be related to its 
ability to bind to cell membranes (1, 5), particularly when not phosphorylated (1). This fits well 
with the lower rate of TNI detection by immunohistochemistry when a phosphorylated tau 
antibody was used. It is possible that the indentation provides a socket for membrane bound 
tau accumulation and that the environment inside the invagination will not favor the presence 
of charged molecules such as the excess of phosphate groups.  
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This tauopathy mouse model-based study opens the possibility of TNIs being present also in 
human FTLD-Tau brains. However, we have performed a preliminary study and we were 
unable to find TNIs in the limited number of analyzed FTLD-Tau cases (I.Ferrer and 
JJ.Hoozemans unpublished observations). Maybe because FTLD-Tau brains are not 
characterized by an excess of essentially non-phosphorylated tau that seems to be the 
common related feature between human HD and mouse P301S brains. But further analysis will 
be required. 
 
 In summary, here we demonstrate that tau alteration in P301S mice is sufficient for the 
formation of TNIs. With the available data we cannot conclude whether these structures are 
pathogenic or innocuous. However, since TNIs are detected both in HD human brain and P301S 
mouse brain whose only common abnormality is increased level of tau, particularly of the 4R-
tau isoform, the detection of TNIs in histopathological analysis of human or mouse model brain 
tissue may become an indicator of increased total tau and/or increased 4R/3R-tau ratio in the 
affected neurons. Our results also indicate that phosphorylation independent tau antibodies 
are more suitable when screening for neurons with nuclear indentations and excess tau by 
monitoring TNI incidence.  
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FIGURE LEGENDS 
Figure 1: Transgene expression of 4R-tau in P301S results in increased total tau levels. 
 A) Scheme of MoPrP-hTau.P301S transgene.  The mouse prion promoter (MoPrP) drives 
expression of the human tau isoform 1N4R, with one N-terminal insert and four tubulin 
binding repeats harboring the P301S FTLD-tau mutation. B) Western blot detection of total tau 
levels with Tau5 antibody in homogenates from cortex, hippocampus and striatum of P301S 
mice respect to WT animals at 20 weeks of age (n=3; Student´s t-test, ** p<0.01, ***p<0.001).  
 
Figure 2: P301S mice show Tau Nuclear Indentations (TNIs) that highly resemble those 
reported in HD brains. 
 (A) Immunohistochemistry with HT-7 and Tau5 antibodies on sagittal sections. Images show 
cortex, striatum and hippocampus of P301S mice. Arrows indicate neurons with 
TNIs. (B) Cortical images of HT-7 and Tau5 immunohistochemistry on sagittal sections of WT 
mice. As a negative control, Tau5 immunohistochemistry on Tau KO mice was performed 
(lower panel). (C) Immunohistochemistry with phospho-specific tau antibodies on P301S mice. 
Tau1 (unphosphorilated tau) in 20 (left panel) and 36 (middle panel)-week old P301S mice, 
with detail of the different shapes that TNIs can adopt in the older mice. Squared neuron with 
TNI in the absence of cytoplasmic tau staining is shown magnified. AT8 (phospho-tau) 
immunostaining in 36-week old P301S mice (right panel). Arrows indicate neurons with 
TNIs. (D) Examples of TNIs detected with HT-7 antibody in sagittal sections of cortex and 
striatum of HD patients. Scale bars correspond to 5 μm. 
 
Figure 3: Ultrastructural analysis of TNIs in P301S mice. 
Immunoelectron microscopy analysis of P301S mice. Examples of cortical neurons harboring 
HT-7 positive rods of different shapes. Red arrows indicate the nuclear indentations with DAB 
precipitate signal. Scale bars correspond to 2 μm. 
 
Figure 4: Confocal analysis confirms that TNIs fill nuclear indentations. 
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Immunofluorescence with HT-7 antibody and DAPI nuclear counterstaining of P301S mice 
neurons. Nuclear indentations and TNIs can be independently observed in cortex, 
hippocampus and striatum. Merge confirms that tau fills the corresponding nuclear 
invagination detected by DAPI. Scale bars correspond to 2.5 μm. 
 
Figure 5: TNI appearance does not correlate with increased incidence of nuclear 
indentations. 
(A) Confocal images showing DAPI nuclear counterstaining (upper images) and HT-7 
immunofluorescence (lower images) in CA1 pyramidal neurons of WT and P301S mice. WT 
neurons show nuclear indentations but they are devoid of HT-7 immunofluorescence. 
However, the vast majority of nuclear indentations In P301S mice harbor HT-7 positive TNIs 
(red arrows). Blue arrows indicate nuclear indentation without TNIs. Scale bars correspond to 
2.5 μm. (B) Quantification of the incidence of TNIs detected by HT-7 immunofluorescence (left 
histogram, n=3) and nuclear indentations detected by DAPI counterstaining (right histogram, 
n=5 for WT, n=7 for P301S) in CA1 hippocampal neurons.  
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